Pennsylvania 2025_0 Regular Session Status: In Committee Sponsors 7 D

SB 1462 — An Act amending the act of September 27, 1961 (P.L.1700, No.699), known as the Pharmacy Act, further providing for definitions; providing for HIV infection prevention medication; and further providing for collaborative drug therapy management and for construction.

Last action — Referred to CONSUMER PROTECTION AND PROFESSIONAL LICENSURE, Sept. 24, 2026

Write to your legislator about it: a free email template →

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed Senate
  4. 4
    Passed House
  5. 5
    To Executive
  6. 6
    Enacted

This bill is in committee in the Senate. Introduced September 24, 2026. It must pass committee before a floor vote.

Next likely step: a committee vote, then a floor vote in the Senate.

In plain language

The bill allows pharmacists to provide HIV infection prevention medication without a prescription.

This bill amends the Pharmacy Act to enable pharmacists to initiate and dispense HIV infection prevention medications directly, without needing a prescription. It details the requirements for pharmacists to do this, including training and insurance obligations.

What this means for you
  • Workers: This bill may empower pharmacists to expand their services and support public health initiatives.

Summary

Increasing Access to HIV Medications

Bill Text

How this bill changes current law

7 changes Share ↗

AI-generated reading aid from the bill's amendatory text — verify against the official bill.

The bill expands the definition of the practice of pharmacy and establishes provisions for pharmacists to initiate, dispense, or administer HIV infection prevention medication.

  • Section 2

    (27) "HIV infection prevention medication" means preexposure prophylaxis HIV medication, postexposure prophylaxis HIV medication or another drug or drug combination approved by the United States Food and Drug Administration that may be used to prevent HIV infection.

    Defines 'HIV infection prevention medication' for clarity in regulations.

  • Section 2

    (28) "Postexposure prophylaxis HIV medication" means a drug or drug combination approved by the United States Food and Drug Administration that may be taken after potential exposure to HIV to prevent HIV infection.

    Defines 'Postexposure prophylaxis HIV medication' to outline its use.

  • Section 2

    (29) "Preexposure prophylaxis HIV medication" means a drug or drug combination approved by the United States Food and Drug Administration that may be taken before potential exposure to HIV to prevent HIV infection.

    Defines 'Preexposure prophylaxis HIV medication' to clarify its context.

  • Section 3.5

    A pharmacist may initiate, dispense or administer HIV infection prevention medication without a prescription in accordance with the Statewide drug therapy protocol and practice guidelines established under subsection (b) and the applicable requirements specified under subsection (c).

    Allows pharmacists to provide HIV prevention medications without a prescription under regulated conditions.

  • Section 3.5

    The board shall promulgate regulations establishing a Statewide drug therapy protocol and practice guidelines under which a pharmacist may initiate, dispense or administer HIV infection prevention medication.

    Mandates the development of guidelines governing pharmacists' administration of HIV medications.

  • Section 3.5

    A pharmacist may initiate, dispense or administer preexposure prophylaxis HIV medication only if all of the following apply: ...

    Sets conditions for pharmacists when dispensing preexposure prophylaxis HIV medications.

  • Section 3.5

    A pharmacist may initiate, dispense or administer a complete course of postexposure prophylaxis HIV medication only if all of the following apply: ...

    Establishes conditions for administering postexposure prophylaxis HIV medications by pharmacists.

Action History

  1. Referred to CONSUMER PROTECTION AND PROFESSIONAL LICENSURE, Sept. 24, 2026

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 6 co-sponsors · 246 not signed on

Sponsors (1)

Co-sponsors (6)

Not signed on (246)

246 members have not signed on to this bill.

Show all 246 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Committees

Subjects

Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does SB 1462 do?
Increasing Access to HIV Medications
Who sponsors SB 1462?
SB 1462 is sponsored by Lindsey M. Williams (Democratic), Jay Costa (Democratic), Art Haywood (Democratic), Christine M. Tartaglione (Democratic), John I. Kane (Democratic), Katie J. Muth (Democratic), and Amanda M. Cappelletti (Democratic).
What is the current status of SB 1462?
This bill is in committee in the Senate. Introduced September 24, 2026. It must pass committee before a floor vote.
Where can I track SB 1462?
Track SB 1462 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on SB 1462

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Stay ahead of SB 1462

Last checked for changes about 1 month ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →